GoodRx Holdings, Inc. (NASDAQ:GDRX) Given Consensus Recommendation of “Hold” by Analysts

GoodRx Holdings, Inc. (NASDAQ:GDRX) has been assigned a consensus recommendation of “Hold” from the nineteen analysts that are currently covering the stock, MarketBeat Ratings reports. One research analyst has rated the stock with a sell rating, eight have given a hold rating and ten have given a buy rating to the company. The average twelve-month price target among analysts that have issued a report on the stock in the last year is $8.78.

GDRX has been the topic of a number of research reports. Bank of America lowered GoodRx from a “buy” rating to an “underperform” rating and cut their price target for the company from $8.00 to $4.50 in a report on Tuesday, January 2nd. TD Cowen boosted their price target on GoodRx from $12.00 to $14.00 and gave the company an “outperform” rating in a report on Friday, March 1st. SVB Leerink initiated coverage on GoodRx in a report on Monday, February 26th. They issued an “outperform” rating and a $8.00 price target on the stock. Leerink Partnrs restated an “outperform” rating on shares of GoodRx in a report on Monday, February 26th. Finally, JPMorgan Chase & Co. upgraded GoodRx from a “neutral” rating to an “overweight” rating and upped their target price for the stock from $7.00 to $10.00 in a report on Friday, March 1st.

Hedge Funds Weigh In On GoodRx

A number of large investors have recently made changes to their positions in the company. Moneta Group Investment Advisors LLC increased its stake in shares of GoodRx by 112,694.0% during the fourth quarter. Moneta Group Investment Advisors LLC now owns 17,148,069 shares of the company’s stock worth $79,910,000 after purchasing an additional 17,132,866 shares during the period. Vanguard Group Inc. increased its stake in shares of GoodRx by 2.1% during the third quarter. Vanguard Group Inc. now owns 8,681,111 shares of the company’s stock worth $48,875,000 after purchasing an additional 177,961 shares during the period. Rubric Capital Management LP bought a new position in GoodRx during the 4th quarter worth $39,348,000. Millennium Management LLC increased its stake in GoodRx by 151.3% during the 4th quarter. Millennium Management LLC now owns 5,318,603 shares of the company’s stock worth $24,785,000 after acquiring an additional 3,202,061 shares during the period. Finally, Ameriprise Financial Inc. increased its stake in GoodRx by 459.0% during the 3rd quarter. Ameriprise Financial Inc. now owns 2,631,227 shares of the company’s stock worth $14,814,000 after acquiring an additional 2,160,541 shares during the period. Institutional investors own 63.77% of the company’s stock.

GoodRx Stock Down 4.1 %

Shares of GoodRx stock opened at $6.55 on Tuesday. The company has a quick ratio of 7.12, a current ratio of 7.12 and a debt-to-equity ratio of 0.85. GoodRx has a 12 month low of $4.14 and a 12 month high of $9.37. The business has a fifty day simple moving average of $6.87 and a 200 day simple moving average of $6.18. The stock has a market cap of $2.59 billion, a PE ratio of -327.34, a price-to-earnings-growth ratio of 3.74 and a beta of 1.42.

GoodRx (NASDAQ:GDRX) last posted its earnings results on Thursday, February 29th. The company reported $0.02 earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of $0.02. GoodRx had a positive return on equity of 2.45% and a negative net margin of 1.18%. The firm had revenue of $196.64 million during the quarter, compared to analysts’ expectations of $195.59 million. Research analysts predict that GoodRx will post 0.23 EPS for the current year.

GoodRx Company Profile

GoodRx Holdings, Inc, together with its subsidiaries, offers information and tools that enable consumers to compare prices and save on their prescription drug purchases in the United States. The company operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and access to negotiated prices.